Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lixisenatide Gains Evidence Of A Weight Loss Benefit

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi/Zealand's GLP-1 agonist lixisenatide continues to show promise in the latest GetGoal results, this time in type 2 diabetics inadequately controlled on sulfonylureas.

You may also be interested in...

Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide

Once-a-day here to stay? With once-weekly taspoglutide just officially rejected by Roche and long-lasting Bydureon delayed on safety, Zealand CEO talks up the virtues of QD GLP-1 analogs.

Novo Nordisk Toughens Long-Term Financial Targets As 2010 Sales Grew By 13%, Profits By 16%

Victoza and its modern insulins franchise drive 2010 revenues growth at Danish diabetes specialist Novo Nordisk.

Sanofi's Lixisenatide/Lantus Combo Could Be A Critical Growth Driver

During business update, French pharma outlines market of 9 million potential patients for the drug combo.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts